|
Biotech News IP law update Regular intellectual property news from Australia and overseas. |
- Innogenetics gets Takeda beta-amyloid antibody patents for Alzheimer's Disease
- Enzo Biochem granted EU patent for technology to treat gene abnormalities
Innogenetics gets Takeda beta-amyloid antibody patents for Alzheimer's Disease
June 9 – Innogenetics and Takeda Chemical Industries have entered into a worldwide licensing agreement by which Innogenetics gains access to Takeda's patent rights for the diagnostic and research use of beta-amyloid antibodies in Alzheimers disease. The brains of Alzheimer's patients contain abnormal deposits of beta-amyloid plaques and bundles of fibres known as neurofibrillary tangles (Tau and phospho-Tau). The Takeda license compliments Innogenetics Tau and phospho-Tau patents, and the combined use of these markers has shown added value in differential diagnosis. The financial terms of this agreement were not disclosed.
[Source: Company Announcement]
Enzo Biochem granted EU patent for technology to treat gene abnormalities
June 14 – The European Patent Office has granted Enzo Biochem a patent for a method of performing targeted cell delivery and incorporation of genetic material into chromosomal DNA without using a viral vector, making it possible to correct certain gene abnormalities. The patent covers constructs and methods that allow a single stranded nucleic acid molecule to displace one of the strands of a double helical molecule. The displacer technology may be used to correct point mutations or effect small deletions or additions in living cells and tissues. 'This technology holds the promise of being one of the most effective means of achieving gene therapy,' said Dean Engelhardt, Executive Vice President of Enzo Biochem. Enzo Biochem holds a complementary patent in the US.
[Source: Company Announcement]
